Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,950,960 papers from all fields of science
Search
Sign In
Create Free Account
TNFSF8 gene
Known as:
CD30L
, Tumor Necrosis Factor (Ligand) Superfamily, Member 8 Gene
, CD30LG
Expand
This gene plays a role in the modulation of T-cell proliferation.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
CD30 Ligand
Cell Death
Cell Proliferation Regulatory Process
Cytokine Receptor Binding
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
CD4+CD3-Cells Regulate the Organization of Lymphoid Tissue and T-Cell Memory for Antibody Responses
P. Lane
,
Mi-Yeon Kim
,
Fabrina Gaspal
,
F. McConnell
International journal of hematology
2006
Corpus ID: 19640628
This review highlights the role of a CD4+CD3- accessory cell in the development of organized lymphoid infrastructures as well as…
Expand
2005
2005
Development and application of a Plasmodium Knowlesi transfection system
Hastings Ozwara Suba
2005
Corpus ID: 73139603
2002
2002
Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy.
Y. Seko
,
S. Ishiyama
,
+11 authors
R. Nagai
Cardiovascular pathology
2002
Corpus ID: 11062437
Highly Cited
2001
Highly Cited
2001
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
M. Huhn
,
S. Sasse
,
+5 authors
A. Engert
Cancer Research
2001
Corpus ID: 15204540
2001
2001
Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy.
E. S. Ekström
,
Å. Bengtsson
,
+6 authors
A. Scheynius
Placenta
2001
Corpus ID: 29089039
The intrauterine environment is characterized by a Th2 dominance during pregnancy, a milieu that also promotes atopic allergy…
Expand
1999
1999
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
S. Barth
,
B. Matthey
,
M. Huhn
,
V. Diehl
,
A. Engert
Cytokines, cellular & molecular therapy
1999
Corpus ID: 28343551
Recombinant DNA technology makes it possible to genetically fuse V genes or cytokines to toxin domains, resulting in…
Expand
1999
1999
Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co‐stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by Coxsackie…
Y. Seko
,
N. Takahashi
,
+7 authors
Y. Yazaki
Journal of Pathology
1999
Corpus ID: 24077948
T‐cell‐mediated myocardial damage has been shown to be involved in acute myocarditis and dilated cardiomyopathy. It is necessary…
Expand
1998
1998
Construction and expression of a soluble form of human CD30 ligand with functional activity
Isabelle F. Powell
,
Tianhong Li
,
H. Jäck
,
T. Ellis
Journal of Leukocyte Biology
1998
Corpus ID: 19671223
CD30 engagement in human lymphoid cells induces pleiotropic cellular responses that affect cellular viability and proliferation…
Expand
Review
1996
Review
1996
Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily
H. Gruss
International journal of clinical & laboratory…
1996
Corpus ID: 24424910
The tumor necrosis factor receptor superfamily at present consists of ten different transmembrane (type I) glycoproteins with…
Expand
1995
1995
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
C. Wendtner
,
B. Schmitt
,
+4 authors
M. Hallek
Cancer Research
1995
Corpus ID: 31686874
CD30 is a transmembrane receptor of the nerve growth factor/tumor necrosis factor receptor superfamily. Its expression associated…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE